2020
DOI: 10.1002/1878-0261.12699 View full text |Buy / Rent full text
|
|

Abstract: Pancreatic ductal adenocarcinoma (PDAC) will soon belong to the top three cancer killers. The only approved specific PDAC therapy targets the epidermal growth factor receptor (EGFR). Although EGFR is a crucial player in PDAC development, EGFR-based therapy is disappointing. In this study, we evaluated the role of the EGFR ligand betacellulin (BTC) in PDAC. The expression of BTC was investigated in human pancreatic cancer specimen. Then, we generated a BTC knockout mouse model by CRISPR/Cas9 technology and a BT… Show more

Help me understand this page

Search citation statements

Order By: Relevance
0
0
0
0
0
0
2
0

Publication Types

Select...

Relationship

0
0

Authors

Journals